Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Novel Augmentation Strategies in Major Depression
Klaus Martiny
Department of Clinical Medicine
3
Citations (Scopus)
5
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Novel Augmentation Strategies in Major Depression'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Exercise Group
100%
Major Depressive Disorder
100%
Remission Rate
84%
Pindolol
76%
Response Rate
69%
Chronos
61%
Light Therapy
61%
Bright Light
53%
Antidepressants
38%
Cortisol
38%
Wake Therapy
38%
Venlafaxine
30%
Dim Light
30%
Sertraline
30%
Sham
30%
Duloxetine
23%
Inclusion Criteria
23%
Sleep Time
23%
Light Treatment
23%
Continuation Phase
23%
Clinician Rating
15%
Treatment Group
15%
Rate-2
15%
Low Cortisol
15%
Salivary Cortisol
15%
Light Sleep
15%
Clinically Significant
15%
Self-assessment Scale
15%
Specialist Practice
15%
Cortisol Measurement
15%
Red Light
7%
High Response Rate
7%
Hamilton Depression Rating Scale (HAM-D)
7%
Biochemical Measures
7%
Continuation Treatment
7%
Metabolizer
7%
Survival Analysis
7%
Medication Treatment
7%
Active Control
7%
General Practitioners
7%
Melancholia
7%
Sleep-wake Cycle
7%
DSM-IV
7%
Zealand
7%
Treatment Resistance
7%
Symptom Checklist-90 (SCL-90)
7%
Depressive Episode
7%
Sham Condition
7%
Quality of Life Scale
7%
Bipolar Disorder
7%
24-hour Urine Collection
7%
Placebo
7%
Control Intervention
7%
Between-group
7%
Cycle Control
7%
Abstinence
7%
Sleep Duration
7%
Clinical Setting
7%
Exercise Program
7%
Daytime Sleep
7%
Therapy Time
7%
Sleep Onset
7%
Double-blind Randomized Controlled Trial
7%
Patient Self-assessment
7%
Control Condition
7%
Mania
7%
Daily Exercise
7%
Day-to-day Variation
7%
Medium-term Outcomes
7%
Psychiatric Ward
7%
Sleep Diary
7%
Time-to-treatment
7%
Saliva
7%
University of Copenhagen
7%
Short-term Outcomes
7%
Treatment Efficacy
7%
Diary Data
7%
Drug Treatment
7%
Major Depression Inventory
7%
Poor Metabolizer
7%
Copenhagen
7%
Psychiatric Research
7%
Medicine and Dentistry
Major Depressive Episode
100%
Hydrocortisone
100%
Spontaneous Remission
100%
Phototherapy
72%
Venlafaxine
36%
Sleep Time
36%
Sertraline
36%
Duloxetine
27%
Side Effect
27%
Antidepressant
27%
Self-Diagnosis
18%
Clinician
18%
Doctor of Philosophy
18%
Antidepressant Activity
18%
Treatment Group
18%
Depressive Disorder
9%
Bech-Rafaelsen Melancholia Scale
9%
Hamilton Rating Scale for Depression
9%
Depression Inventory
9%
Survival Analysis
9%
Quality of Life
9%
Bipolar Disorder
9%
Antidepressant Medication
9%
Randomized Controlled Trial
9%
DSM-IV
9%
Treatment Response
9%
General Practitioner
9%
Checklist
9%
Seasonal Affective Disorder
9%
Thyroid Gland
9%
Pharmacotherapy
9%
Placebo
9%
Patient Recruitment
9%
Abstinence
9%
Mental Health
9%
Pharmacology, Toxicology and Pharmaceutical Science
Hydrocortisone
100%
Remission
100%
Major Depression
100%
Pindolol
90%
Antidepressant
54%
Sertraline
36%
Venlafaxine
36%
Duloxetine
27%
Side Effect
27%
Treatment Group
18%
Randomized Controlled Trial
9%
Bipolar Disorder
9%
Placebo
9%
Depressive Disorder
9%
Melancholia
9%
DSM-IV
9%
Patient Recruitment
9%
Tablet
9%
Seasonal Affective Disorder
9%
Pharmacotherapy
9%
Nursing and Health Professions
Major Depression
100%
Remission
100%
Hydrocortisone
90%
Phototherapy
72%
Antidepressant
54%
Sleep Time
36%
Side Effect
27%
Self Evaluation
18%
Treatment Group
18%
Doctor of Philosophy
18%
Hamilton Depression Rating Scale
9%
Survival Analysis
9%
Psychiatric Department
9%
Bipolar Disorder
9%
Depression Inventory
9%
Bech-Rafaelsen Melancholia Scale
9%
Checklist
9%
Depressive Disorder
9%
DSM-IV
9%
General Practitioner
9%
Quality of Life
9%
Treatment Response
9%
Placebo
9%
Seasonal Affective Disorder
9%
Hydrocortisone Urine Level
9%
Neuroscience
Cortisol
100%
Major Depressive Disorder
100%
Antidepressant
54%
Venlafaxine
36%
Sleep Time
36%
Sertraline
36%
Duloxetine
27%
Depressive Disorder
9%
Bipolar Disorder
9%
Placebo
9%
Hamilton Rating Scale for Depression
9%
Seasonal Affective Disorder
9%
Sleep Waking Cycle
9%
Survival Analysis
9%
Randomized Controlled Trial
9%
Thyroid
9%
Melancholic Depression
9%